LHFPL3: A Potential Drug Target and Biomarker (G375612)

Target Name: LHFPL3

NCBI ID: G375612

LHFPL3

LHFPL3: A Potential Drug Target and Biomarker

Introduction

LHFPL3 (LHFP-like protein 3) is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has significant implications for the development of new treatments.

Structure and Function

LHFPL3 is a member of the LHFPL family, which is characterized by the presence of a unique nucleotide-binding oligomerization domain (NBO domain) and a hydrophobic oligomerization domain (HBO domain). LHFPL3 has a calculated molecular mass of 11.9 kDa and a pre-fusion potential of 16.9 kDa. Its NBO domain is a small protein that contains a single nucleotide, which can bind to specific DNA sequences. This domain is known to play a role in the regulation of gene expression and has been implicated in the development and progression of various diseases.

In addition to its NBO domain, LHFPL3 has a hydrophobic domain, which is known to be involved in protein-protein interactions and may contribute to LHFPL3's unique function. This domain is located at the C-terminus of the protein and consists of a series of amino acids that are involved in the formation of a hydrophobic loop. This loop is thought to interact with other proteins and may contribute to LHFPL3's stability or interactions with other cellular components.

Expression and Regulation

LHFPL3 is expressed in various tissues and cells, including cancer cells, neurodegenerative neurons, and immune cells. Its expression has been shown to be regulated by various factors, including DNA methylation, histone modification, and post-transcriptional modification. For example, studies have shown that LHFPL3 is regulated by DNA methylation, which can affect its stability and localization to specific cellular compartments. Additionally, histone modification, such as histone H3 lysine 27 trimethylation (H3K27me3), has been shown to play a role in the regulation of LHFPL3 expression.

In addition to its expression, LHFPL3 has also been shown to be regulated by post-transcriptional modification, such as phosphorylation and ubiquitination. For example, studies have shown that LHFPL3 can be phosphorylated by various kinases, including Akt, Stat3, and Src, which can affect its stability and function. Additionally, LHFPL3 has been shown to be ubiquitinated, which can also affect its stability and localization to specific cellular compartments.

Drug Targeting and Biomarker Potential

LHFPL3's unique structure and function make it an attractive target for drug research. Its NBO domain and hydrophobic domain have been shown to play a role in the regulation of gene expression, which can make it a potential target for small molecules that can modulate gene expression. Additionally, LHFPL3's expression is regulated by various factors, including DNA methylation, histone modification, and post-transcriptional modification, which can make it a potential target for drugs that can modulate these factors.

In addition to its potential as a drug target, LHFPL3 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for researchers to investigate the role of this protein in the development and progression of these diseases.

Conclusion

LHFPL3 is a protein that has significant potential as a drug target and biomarker. Its unique structure and function have made it an attractive target for

Protein Name: LHFPL Tetraspan Subfamily Member 3

The "LHFPL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LHFPL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets